Search

Your search keyword '"Novello, S"' showing total 1,359 results

Search Constraints

Start Over You searched for: Author "Novello, S" Remove constraint Author: "Novello, S"
1,359 results on '"Novello, S"'

Search Results

6. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

8. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study

9. LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study

10. 121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy

13. Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?

17. EP01.01-12 Binge-Watching Frequency and Tobacco Use in Adolescents: Data from “Blaam Smoke-Free Movie” Program

18. MA07.09 Adapted Physical Activity (AMAti) Program for Lung Cancer Patients Realized by WALCE (Women Against Lung Cancer in Europe)

19. MA11.08 IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC

20. MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02

22. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study

23. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016

28. Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study

29. P002 Adjuvant chemotherapy for resected early-stage triple negative breast cancer

30. 40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC

31. PP01.17 Sotorasib in Advanced KRAS p.G12C–Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)

33. Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey

34. 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

37. Fatigue in lung cancer patients: symptom burden and management of challenges

38. EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

39. EP10.01-015 The Role of CT-Scan as a Body Composition Tool in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.

40. OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer

41. P1.11-01 Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung

42. EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity

43. EP16.03-040 Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base

44. EP06.01-006 Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis

45. 1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)

47. EP05.01-024 Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study

48. LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

49. 989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)

Catalog

Books, media, physical & digital resources